Aisling Capital Management LP

Holdings as of 2026-06-30, filed 2026-08-13

This is history, not a current position. These holdings describe 2026-06-30, and the report became public 44 days later. The portfolio has changed since.

Aggregates

computed from the positions below
Positions reported
14
Value reported by manager
$471.6M
Sum of our stored positions
$471.6M
should match the line above
Disclosure lag
44 d
quarter end to filing
Top 5 concentration
94.4%
of the positions shown
New positions
0
vs previous quarter
Exited
0
vs previous quarter
Option positions
0
puts and calls

Positions

14 largest shown
IssuerClassValueSharesTypeCUSIP
BRIDGEBIO PHARMA INCCOM$341.8M4,589,61110806X102
MONTE ROSA THERAPEUTICS INCCOM$37.6M1,555,66461225M102
SYNDAX PHARMACEUTICALS INCCOM$28.8M1,316,80687164F105
COMPASS PATHWAYS PLCSPONSORED ADS$20.3M1,432,33620451W101
BICARA THERAPEUTICS INCCOM$16.9M568,919055477103
BRIDGEBIO ONCOLOGY THERAPEUTCOM NEW$7.8M1,018,018107924102
SCHOLAR ROCK HLDG CORPCOM$4.2M77,03180706P103
UROGEN PHARMA LTDCOM$4M108,000M96088105
BIOMEA FUSION INCCOM$3M2,048,75709077A106
ACLARIS THERAPEUTICS INCCOM$2.3M434,45500461U105
EUPRAXIA PHARMACEUTICALS INCCOM$2.1M325,00029842P105
VTV THERAPEUTICS INCCL A NEW$1.9M50,000918385204
MARKER THERAPEUTICS INCCOM NEW$478.3K325,37057055L206
ONKURE THERAPEUTICS INCCOM CL A$404K88,60768277Q105
Values are shown exactly as filed. Before 2023 managers reported in thousands of dollars and afterwards in whole dollars; the reporting unit is not always determinable from the document, so nothing is converted automatically.

Source: U.S. Securities and Exchange Commission, Form 13F · as of 2026-08-13